103P2D6: tissue specific protein highly expressed in various cancers

A polynucleotide that encodes an 103P2D6-related protein, wherein the polypeptide includes a motif-bearing amino acid sequence set forth in Table XIX.

A polynucleotide that encodes an 103P2D6-related protein, wherein the polypeptide comprises an HLA class I A1, A2, A3, A24, B7, B27, B58, B62 supermotif, or an HLA class II DR supermotif set forth in Table IV (B) or an Alexander pan DR binding epitope supermotif or an HLA DR3 motif.

An isolated 103P2D6-related protein.

An antibody or fragment thereof that specifically binds to a 103P2D6-related protein.

An assay for detecting the presence of a 103P2D6-related protein or polynucleotide in a biological sample comprising:

• contacting the sample with an antibody or polynucleotide, respectively, that specifically binds to the 103P2D6-related protein or polynucleotide, respectively, and detecting the binding of 103P2D6-related protein or polynucleotide, respectively, in the sample thereto.

An assay for detecting the presence of 103P2D6 mRNA in a biological sample comprising:

• (a) producing cDNA from the sample by reverse transcription using at least one primer;
• (b) amplifying the cDNA so produced using 103P2D6 polynucleotides as sense and antisense primers to amplify 103P2D6 cDNAs therein;
• (c) detecting the presence of the amplified 103P2D6 cDNA, wherein the 103P2D6 polynucleotides used as the sense and antisense probes are capable of amplifying the 103P2D6 cDNA contained within the plasmid as deposited with American Type Culture Collection as Accession No. PTA-1895 or PTA-1155.

Use of an 103P2D6-related protein, a vector comprising a polynucleotide encoding a single chain monoclonal antibody that immunospecifically binds to an 103P2D6-related protein, an antisense polynucleotide complementary to a polynucleotide having 103P2D6 coding sequences, or a ribozyme capable of cleaving a polynucleotide having 103P2D6 coding sequences, for the preparation of a composition for treating a patient with a cancer that expresses 103P2D6.

A pharmaceutical composition comprising an 103P2D6-related protein, an antibody or fragment thereof that specifically binds to an 103P2D6-related protein, a vector comprising a polynucleotide encoding a single chain monoclonal antibody that immunospecifically binds to an 103P2D6-related protein, a polynucleotide comprising an 103P2D6-related protein coding sequence, an antisense polynucleotide complementary to a polynucleotide having an 103P2D6 coding sequences or a ribozyme capable of cleaving a polynucleotide having 103P2D6 coding sequences and, optionally, a physiologically acceptable carrier.

A method of inducing an immune response to an 103P2D6 protein, said method comprising:

• providing a 103P2D6-related protein T cell or B cell epitope;
• contacting the epitope with an immune system T cell or B cell respectively, whereby the immune system T cell or B cell is induced.